Skip to main content

Table 1 Characteristics of the study sample according to the intake of systemic antiherpetic drugs. “Echantillon Généraliste des Bénéficiaires.” 2009–2017

From: Antiherpetic drugs: a potential way to prevent Alzheimer’s disease?

  Study sample (N=68291)N (%) No systemic antiherpetics (N=61649)N (%) Systemic antiherpetics (N=6642) N (%)
Age at inclusion, mean ± standard deviation 76 ± 8 76 ± 8 74 ± 6
Sex - men 28286 (41.42) 25975 (42.13) 2311 (34.79)
Complementary health insurance for low-income people at inclusion 883 (1.29) 799 (1.30) 84 (1.26)
Comorbidities at inclusion
 Hypertension 40471 (59.26) 36400 (59.04) 4071 (61.29)
 Diabetes 10584 (15.50) 9668 (15.68) 916 (13.79)
 Heart disease 19753 (28.92) 17866 (28.98) 1887 (28.41)
 Stroke 1294 (1.89) 1194 (1.94) 100 (1.51)
 Hypercholesterolemia 25590 (37.47) 22737 (36.88) 2853 (42.95)
Intake of nonsteroidal anti-inflammatory drugs the year before inclusion
 0 43184 (63.24) 39695 (64.39) 3489 (52.53)
 1 à 10 20246 (29.65) 17735 (28.77) 2511 (37.80)
 ≥10 4861 (7.12) 4219 (6.84) 642 (9.67)
Intake of systemic glucocorticoids the year before inclusion
 0 55301 (80.98) 50385 (81.73) 4916 (74.01)
 1 à 10 12081 (17.69) 10465 (16.98) 1615 (24.31)
 ≥10 910 (1.33) 799 (1.30) 111 (1.67)
Intake of inhaled glucocorticoids the year before inclusion
 0 61175 (89.58) 55429 (89.91) 5746 (86.51)
 1 à 10 5730 (8.39) 4975 (8.07) 755 (11.37)
 ≥10 1386 (2.03) 1245 (2.02) 141 (2.12)
Number of outpatient medical consultations the year before inclusion, median [IQR] 2 [06] 2 [06] 4 [18]
Number of different treatments the year before inclusion, median [IQR] 12 [618] 11 [518] 15 [921]
  1. Abbreviations: IQR interquartile range